Stephen A. Migueles

Stephen A. Migueles

Auto-generated profile, based on publicly available information

Stephen A. Migueles

Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
IPIulia Popescu
Iulia Popescu
MPMatthew R. Pipeling
Matthew R. Pipeling
HMHannah Mannem
Hannah Mannem
PSPali D. Shah
Pali D. Shah
JOJonathan B. Orens
Jonathan B. Orens
JMJohn F. McDyer
John F. McDyer
CMV remains an important opportunistic pathogen in solid organ and hematopoietic cell transplantation, particularly in lung transplant recipients (LTRs). LTRs mismatched for CMV (donor+/recipient−; D+R−) are at high risk for active CMV infection and increased mortality; however, the immune correlates of viral control remain incompletely understood. We prospectively studied 27 D+R− LTRs during primary CMV infection to determine whether acute CD4+ T cell parameters differentiated the capacity for viral control during early chronic infection. Unexpectedly, the T-box transcription factor, T-bet, was expressed at low levels in CD4+ compared with CD8+ T cells during acute primary infection. However, the capacity for in vitro CMV phosphoprotein 65–specific proliferation and CD4+T-bet+ induction differentiated LTR controllers from early viremic relapsers, correlating with granzyme B loading and effector multifunction. Furthermore, impaired CMV-specific proliferative responses from relapsers, along with T-bet, and effector function could be significantly rescued, most effectively with phosphoprotein 65 Ag and combined exogenous IL-2 and IL-12. Acute CD4+ T cell CMV–specific proliferative and effector responses were highly IL-12–dependent in blocking studies. In addition, we generated monocyte-derived dendritic cells using PBMC obtained during primary infection from relapsers and observed impaired monocyte-derived dendritic cell differentiation, a reduced capacity for IL-12 production, but increased IL-10 production compared with controls, suggesting an APC defect during acute CMV viremia. Taken together, these data show an important role for CMV-specific CD4+ effector responses in differentiating the capacity of high-risk LTRs to establish durable immune control during early chronic infection and provide evidence for IL-12 as a key factor driving these responses.

15 December 2023 in Science
Verified
Journal Article
Closed access
SMStephen A. Migueles
Stephen A. Migueles
DNDanielle M. Nettere
Danielle M. Nettere
NGNoah V. Gavil
Noah V. Gavil
LWLawrence T. Wang
Lawrence T. Wang
STSushila A. Toulmin
Sushila A. Toulmin
MCMark Connors
Mark Connors
Current HIV vaccines designed to stimulate CD8 + T cells have failed to induce immunologic control upon infection. The functions of vaccine-induced HIV-specific CD8 + T cells were investigated here in detail. Cytotoxic capacity was significantly lower than in HIV controllers and was not a consequence of low frequency or unaccumulated functional cytotoxic proteins. Low cytotoxic capacity was attributable to impaired degranulation in response to the low antigen levels present on HIV-infected targets. The vaccine-induced T cell receptor (TCR) repertoire was polyclonal and transduction of these TCRs conferred the same reduced functions. These results define a mechanism accounting for poor antiviral activity induced by these vaccines and suggest that an effective CD8 + T cell response may require a vaccination strategy that drives further TCR clonal selection.

23 August 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
EWEoghann White
Eoghann White
LPLaura Papagno
Laura Papagno
ASAssia Samri
Assia Samri
KSKenji Sugata
Kenji Sugata
BHBoris Hejblum
Boris Hejblum
VAVictor Appay
Victor Appay

9 November 2020 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
SMStephen A. Migueles
Stephen A. Migueles
DRDaniel. C. Rogan
Daniel. C. Rogan
NGNoah V. Gavil
Noah V. Gavil
EKElizabeth P. Kelly
Elizabeth P. Kelly
STSushila A. Toulmin
Sushila A. Toulmin
MCMark Connors
Mark Connors
Antigen-specific CD8+T cells play a major role in controlling most virus infections, primarily by perforin (PRF)- and granzyme B (GrB)-mediated apoptosis. There is considerable controversy regarding whether PRF is constitutively expressed, rapidly increased similarly to a cytokine, or delayed in its expression with more prolonged stimulation in virus-specific memory CD8+T cells. In this study, the degree of cytotoxic capacity of virus-specific memory CD8+T cells was directly proportional to the content of lytic molecules, which required antigenic stimulation over several days for maximal levels. This appeared to be modulated by increases in GrB transcription and microRNA-mediated posttranscriptional regulation of PRF expression. Clarifying the requirements for maximal cytotoxic capacity is critical to understanding how viral clearance might be mediated by memory cells and what functions should be induced by vaccines and immunotherapies.

15 December 2020 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
AUAnalia Uruena
Analia Uruena
ICIsabel Cassetti
Isabel Cassetti
NKNeena Kashyap
Neena Kashyap
CDClaire Deleage
Claire Deleage
JEJacob D Estes
Jacob D Estes
SMStephen A Migueles
Stephen A Migueles
Possible human immunodeficiency virus (HIV)-1 clearance has rarely been reported. In this study, we describe a unique case of an HIV-positive, combination antiretroviral therapy (cART)-experienced woman with prior acquired immunodeficiency syndrome (AIDS) who has not experienced viral rebound for over 12 years since discontinuing cART. Leukapheresis, colonoscopy, and lymph node excision were performed for detailed examination of virologic (including HIV reservoir) and immunologic features. Comparisons were made with chronically infected patients and healthy controls. No HIV-specific antibodies were detected in serum. Plasma HIV ribonucleic acid (RNA) levels were <0.2 copies/mL, and, except for low-frequency HIV deoxyribonucleic acid (DNA)+ cells in lymph node tissue (1 copy/3 × 106 cells), HIV antigen could not be detected by quantitative virus outgrowth (<0.0025 infectious units/106 CD4+ T cells) or by most measurements of HIV RNA or DNA in blood, lymph node, or gut-associated mononuclear cells. Human immunodeficiency virus-specific T-cell responses were detectable but low. Brain imaging revealed a prior biopsy site and persistent white matter disease since 1996. Human immunodeficiency virus DNA+ cells in the 1996 brain biopsy specimen confirmed her identity and initial HIV diagnosis. This represents the first report of complete seroreversion, prolonged posttreatment virus suppression, a profoundly small HIV reservoir, and persistent HIV-specific T cells in an adult with prior AIDS.

18 December 2024 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
BEBrian P Epling
Brian P Epling
ALAndrea Lisco
Andrea Lisco
MMMaura Manion
Maura Manion
ELElizabeth Laidlaw
Elizabeth Laidlaw
FGFrances Galindo
Frances Galindo
ISIrini Sereti
Irini Sereti
Background: Despite suppressive antiretroviral therapy (ART), 15%–30% of people with human immunodeficiency virus (HIV) experience a limited recovery of CD4 T cells. Although autoantibodies against the CD4 receptor have previously been identified in people with HIV (PWH), little is known about their longitudinal impact on CD4 T-cell reconstitution. Methods: Anti-CD4 autoantibodies were evaluated by the fluid-phase luciferase immunoprecipitation systems immunoassay in ART-naive people with advanced HIV (CD4 count ≤100 cells/µL), PWH with CD4 count >200 cells/µL, long-term nonprogressors, people with idiopathic CD4 lymphopenia, people with autoimmune lymphoproliferative syndrome, and healthy volunteers without HIV. In the participants with advanced HIV, we assessed the association of anti-CD4 autoantibodies at ART initiation with CD4 recovery over a median follow-up of 192 weeks. Results: Anti-CD4 autoantibodies were identified in 29% (61/210) of ART-naive participants with advanced HIV but were absent in people without HIV. Female PWH showed a 4-fold higher prevalence (P < .001) of anti-CD4 autoantibodies compared to males. After ART initiation, people with advanced HIV with anti-CD4 autoantibodies exhibited an overall slower rate of CD4 reconstitution (5.8 vs 6.6 cells/µL/month, P = .007) and lower week 192 CD4 count (268 vs 355 cells/µL, P = .037). Incidental, clinically indicated immunosuppressive therapy in these participants was associated with an improved rate of CD4 reconstitution (P = .0019) and higher week 192 CD4 count (551 vs 268 cells/µL, P = .019). Conclusions: People with advanced HIV harboring anti-CD4 autoantibodies at ART initiation demonstrated a slower rate and extent of CD4 reconstitution after 4 years. Incidental immunosuppressive therapy was associated with increased CD4 counts in these participants.